NMS-P937 has been validated as an anticancer agent against different preclinical rodent, and nonrodent models of acute myelogenous leukemia (AML), exhibiting inhibition of PLK-1-mediated phosphorylation of TCTP at Ser46 and triggering the apoptosis induction. The gene discussed is TPT1; the disease is acute myeloid leukemia.